Division of GlaxoSmithKline PLC
Latest From GlaxoSmithKline KK
Merck China R&D head leaving after overseeing several high-profile drug approvals, while Novo Nordisk China's marketing head will lead the firm's operations in Oceania.
The spring cherry blossom has ushered in a flurry of new executives to the industry in the Asia Pacific, particularly in Japan where the new fiscal years starts in April for most companies. GSK has taken a bold step to appoint an executive with a previous startup background to its senior leadership in Japan, while Daiichi Sankyo has set up a special division for overseas expansion. Nippon Shinyaku and IQVIA Japan have also made new appointments.
Pfizer Japan, Novartis Pharma KK, Chugai Pharmaceutical, GlaxoSmithKline KK and other Japan subsidiaries or allies of foreign drug makers are planning to introduce new cancer drugs in the country.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- OTC, Consumer
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
- Philippe Fauchet, Pres.
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.